N/A

Leidos Biomedical Research, Inc., Frederick MD

Investigators

Abstract

The National Cancer Institute (NCI)?s Clinical Proteomic Tumor Analysis Consortium (CPTAC) comprises of an Antibody Program that comprehensively characterizes affinity reagents for cancer research via its Antibody Characterization Laboratory (ACL) located at the Frederick National Laboratory for Cancer Research (FNLCR) in Frederick, MD. Within the ACL, a Proteomic Characterization Laboratory (PCL) pilot is to be established for comprehensive Mass Spectrometry (MS)-based proteomic characterization (global- and phospho-proteomes) and targeted (fit-for-purpose) assays.